ANCA-associated vasculitis: Is there a role for neutrophil apoptosis in autoimmunity?

Expert Review of Clinical Immunology

Volumn 2, Issue 2, 2006, Pages 237-244

  Harper, Lorraine ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYTOKINE; ETANERCEPT; INFLIXIMAB; NEUTROPHIL CYTOPLASMIC ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ANCA ASSOCIATED VASCULITIS; ANTIBODY PRODUCTION; ANTIGEN PRESENTATION; APOPTOSIS; AUTOIMMUNITY; BLOOD VESSEL INJURY; CELL ACTIVATION; CLINICAL TRIAL; CROHN DISEASE; DENDRITIC CELL; ENDOTHELIUM CELL; ENDOTHELIUM LESION; HUMAN; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFLAMMATORY CELL; KIDNEY; LEUKOCYTE ACTIVATION; LUNG; NEUTROPHIL; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PHAGOCYTOSIS; PLASMAPHERESIS; RELAPSE; REVIEW; SEPSIS; SYSTEMIC VASCULITIS;

EID: 33748505668     PISSN: 1744666X     EISSN: None     Source Type: Journal    
DOI: 10.1586/1744666X.2.2.237     Document Type: Review

References (81)

1. Jennette JC, Wilkman AS, Falk RJ. Antineutrophil cytoplasmic autoantibody-associated glomerulonephritis and vasculitis. Am. J. Pathol. 135, 921-930 (1989).
2. Jennette JC, Falk RJ, Andrassy K et al. Nomenclature of systemic vasculitides, the proposal of an International Consensus Conference. Arthritis Rheum. 37, 187-192 (1994).
3. Falk RJ, Terrell RS, Charles LA, Jennette JC. Antineutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc. Natl Acad. Sci. USA 87, 4115-4119 (1990).
4. Falk RJ, Hogan S, Carey TS, Jennette JC. Clinical course of antineutrophil cytoplasmic autoantibody-associated glomerulonephritis and systemic vasculitis. Ann. Int. Med. 113, 656-663 (1990).
5. Hogan S, Nachman P, Wilkman A, Jennette J, Falk R, network. Tgdc. Prognostic markers in patients with antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J. Am. Soc. Nephrol. 7, 23-32 (1996).
6. Hauer HA, Bajema IM, van Houwelingen HC et al. Determinants of outcome in ANCA-associated glomerulonephritis, a prospective clinico-histopathological analysis of 96 patients. Kidney Int. 62(5), 1732-1742 (2002).
7. Hauer HA, Bajema IM, van Houwelingen HC et al. Renal histology in ANCA-associated vasculitis, differences between diagnostic and serologic subgroups. Kidney Int. 61(1), 80-89 (2002).
8. Harper L, Savage C. Pathogenesis of ANCA-associated systemic vasculitis. J. Pathol. 190, 349-359 (2000).
9. Bansal PJ, Tobin MC. Neonatal microscopic polyangiitis secondary to transfer of maternal myeloperoxidase-antineutrophil cytoplasmic antibody resulting in neonatal pulmonary hemorrhage and renal involvement. Ann. Allergy Asthma Immunol. 93(4), 398-401 (2004).
10. Choi H, Merkel P, Walker A, Niles J. Drug-associated ANCA-positive vasculitis, prevalence among patients with high titres of antiMPO antibodies. Arthritis Rheum. 43, 401-413 (2000).
11. Cohen Tervaert J, Popa E, Bos N. The role of superantigens in vasculitis. Curr. Opin. Rheum. 11, 24-33 (1999).
12. Lane SE, Watts RA, Bentham G, Innes NJ, Scott DG. Are environmental factors important in primary systemic vasculitis? A case-control study. Arthritis Rheum. 48(3), 814-823 (2003).
13. Hagen E, Daha M, Hermans J, Andrassay K, Csernok E, Gaskin G et al. Diagnostic value of standardised assays for antineutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. Kidney Int. 53, 743-753 (1998).
14. Boomsma MM, Stegeman CA, van der Leij MJ et al. Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels, a prospective study. Arthritis Rheum. 43(9), 2025-2033 (2000).
15. Xiao H, Heeringa P, Hu P et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J. Clin. Invest. 110(7), 955-963 (2002).
16. Little MA, Smyth CL, Yadav R et al. Antineutrophil cytoplasm antibodies directed against myeloperoxidase augment leukocyte-microvascular interactions in vivo. Blood 106(6), 2050-2088 (2005).
17. Pfister H, Ollert M, Frohlich LF et al. Antineutrophil cytoplasmic autoantibodies against the murine homolog of proteinase 3 (Wegener autoantigen) are pathogenic in vivo. Blood 104, 1411-1418 (2004).
18. Travis WD, Hoffman GS, Leavitt RY, Pass HI, Fauci AS. Surgical pathology of the lung in Wegener's granulomatosis. Review of 87 open lung biopsies from 67 patients. Am. J. Surg. Pathol. 15(4), 315-333 (1991).
19. Cockwell P, Brooks C, Adu D, Savage C. Interleukin-8, a pathogenetic role in antineutrophil cytoplasmic autoantibody (ANCA)-associated glomerulonephritis. Kidney Int. 55, 852-863 (1999).
20. Xiao H, Heeringa P, Liu Z et al. The role of neutrophils in the induction of glomerulonephritis by antimyeloperoxidase antibodies. Am. J. Pathol. 167(1), 39-45 (2005).
21. Muller Kobold A, Kallenberg C, Cohen-Tervaert J. Leucocyte membrane expression of proteinase 3 correlates with disease activity in patients with Wegener's granulomatosis. Br. J. Rheum. 37, 901-907 (1998).
22. Rarok AA, Stegeman CA, Limburg PC, Kallenberg CG. Neutrophil membrane expression of proteinase 3 (PR3) is related to relapse in PR3-ANCA-associated vasculitis. J. Am. Soc. Nephrol. 13(9), 2232-2238 (2002).
23. Schreiber A, Luft FC, Kettritz R. Membrane proteinase 3 expression and ANCA-induced neutrophil activation. Kidney Int. 65(6), 2172-2183 (2004).
24. Huugen D, Xiao H, van Esch A et al. Aggravation of antimyeloperoxidase antibody-induced glomerulonephritis by bacterial lipopolysaccharide, role of tumor necrosis factor-α. Am. J. Pathol. 167(1), 47-58 (2005).
25. Williams JM, Ben-Smith A, Hewins P et al. Activation of the G(i) heterotrimeric G-protein by ANCA IgG F(ab′)2 fragments is necessary but not sufficient to stimulate the recruitment of those downstream mediators used by intact ANCA IgG. J. Am. Soc. Nephrol. 14(3), 661-669 (2003).
26. Hewins P, Williams JM, Wakelam MJ, Savage CO. Activation of Syk in neutrophils by antineutrophil cytoplasm antibodies occurs via Fcγ receptors and CD18. J. Am. Soc. Nephrol. 15(3), 796-808 (2004).
27. Radford D, Lord J, Savage C. The activation of the neutrophil respiratory burst by antineutrophil cytoplasm autoantibody (ANCA) from patients with systemic vasculitis requires tyrosine kinases and protein kinase C activation. Clin. Exp. Immunol. 118, 171-179 (1999).
28. Ben-Smith A, Dove S, Martin A, Wakelam M, Savage C. Antineutrophil cytoplasmic autoantibodies from patients with systemic vasculitis activate neutrophils via distinct signalling cascades compared to conventional Fcγ receptor ligation. Blood 981, 1448-1455 (2001).
29. Williams JM, Savage CO. Characterization of the regulation and functional consequences of p21ras activation in neutrophils by antineutrophil cytoplasm antibodies. J. Am. Soc. Nephrol. 16(1), 90-96 (2005).
30. Reumaux D, Kuijpers TW, Hordijk PL, Duthilleul P, Roos D. Involvement of Fcγ receptors and β2 integrins in neutrophil activation by antiproteinase-3 or antimyeloperoxidase antibodies. Clin. Exp. Immunol. 134(2), 344-350 (2003).
31. Savage CO, Harper L, Holland M. New findings in pathogenesis of antineutrophil cytoplasm antibody-associated vasculitis. Curr. Opin. Rheumatol. 14(1), 15-22 (2002).
32. Calderwood JW, Williams JM, Morgan MD, Nash GB, Savage CO. ANCA induces {β}2 integrin and CXC chemokine-dependent neutrophil-endothelial cell interactions that mimic those of highly cytokine-activated endothelium. J. Leukoc. Biol. 30, 33-43 (2004).
33. Ren Y, Savill J. Apoptosis, the importance of being eaten. Cell Death Differ. 5(7), 563-568 (1998).
34. Henson PM, Bratton DL, Fadok VA. Apoptotic cell removal. Curr. Biol. 11(19), R795-R805 (2001).
35. Herrmann M, Voll RE, Zoller OM, Hagenhofer M, Ponner BB, Kalden JR. Impaired phagocytosis of apoptotic cell material by monocyte-derived macrophages from patients with systemic lupus erythematosus. Arthritis Rheum. 41, 1241-1250 (1998).
36. Taylor PR, Carugati A, Fadok VA et al. A hierarchical role for classical pathway complement proteins in the clearance of apoptotic cells in vivo. J. Exp. Med. 192(3), 359-366 (2000).
37. Ogden C, deCathelineau A, Hoffmann P et al. C1q and mannose binding lectin engagement of cell surface calreticulin and CD91 initiates macropinocytosis and uptake of apoptotic cells. J. Exp. Med. 194, 781-795 (2001).
38. Yamamoto T, Kaburagi Y, Izaki S, Tanaka T, Kitamura K. Leukocytoclasis, ultrastructural in situ nick end labeling study in anaphylactoid purpura. J. Dermatol. Sci. 24(3), 158-165 (2000).
39. Mackiewicz Z, Rimkevicius A, Petersen J et al. Macrophages overloaded with tissue debris in Wegener's granulomatosis. Ann. Rheum. Dis. 64(8), 1229-1232 (2005).
40. Kamesh L, Heward J, Williams J, Savage COS, Harper L. No association between mannose binding lectin and ANCA-associated vasculitis. Kidney Blood Press. Res. 28, 176 (2005).
41. Persson U, Truedsson L, Westman K, Segelmark M. C3 and C4 in antineutrophil cytoplasmic autoantibody (ANCA)-positive vasculitis. Clin. Exp. Immunol. 116, 379-382 (1999).
42. Manderson AP, Botto M, Walport MJ. The role of complement in the development of systemic lupus erythematosus. Annu. Rev. Immunol. 22 431-456 (2004).
43. Gershov D, Kim S, Brot N, Elkon KB. C-reactive protein binds to apoptotic cells, protects the cells from assembly of the terminal complement components, and sustains an anti-inflammatory innate immune response, implications for systemic autoimmunity. J. Exp. Med. 192(9), 1353-1364 (2000).
44. Familian A, Zwart B, Huisman HG et al. Chromatin-independent binding of serum amyloid P component to apoptotic cells. J. Immunol. 167(2), 647-654 (2001).
45. Gaipl US, Kuenkele S, Voll RE et al. Complement binding is an early feature of necrotic and a rather late event during apoptotic cell death. Cell Death Differ. 8(4), 327-334 (2001).
46. van Rossum AP, Fazzini F, Limburg PC et al. The prototypic tissue pentraxin PTX3, in contrast to the short pentraxin serum amyloid P, inhibits phagocytosis of late apoptotic neutrophils by macrophages. Arthritis Rheum. 50(8), 2667-2674 (2004).
47. Fazzini F, Peri G, Doni A et al. PTX3 in small-vessel vasculitides, an independent indicator of disease activity produced at sites of inflammation. Arthritis Rheum. 44(12), 2841-2850 (2001).
48. Harper L, Ren Y, Savill J, Adu D, Savage C. Dysregulated neutrophil apoptosis in systemic vasculitis. Am. J. Pathol. 157, 211-220 (2000).
49. Fadok V, Voelker D, Campbell P, Cohen J, Bratton D, Henson P. Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J. Immunol. 148, 2207-2216 (1992).
50. Asano K, Miwa M, Miwa K et al. Masking of phosphatidylserine inhibits apoptotic cell engulfment and induces autoantibody production in mice. J. Exp. Med. 200(4), 459-467 (2004).
51. Vandivier RW, Fadok VA, Hoffmann PR et al. Elastase-mediated phosphatidylserine receptor cleavage impairs apoptotic cell clearance in cystic fibrosis and bronchiectasis. J. Clin. Invest. 109(5), 661-670 (2002).
52. Henriksen PA, Devitt A, Kotelevtsev Y, Sallenave JM. Gene delivery of the elastase inhibitor elafin protects macrophages from neutrophil elastase-mediated impairment of apoptotic cell recognition. FEBS Lett. 574(1-3), 80-84 (2004).
53. Esnault VL. ANCA-positive vasculitis and α 1-antitrypsin deficiency, could free ANCA antigens released by neutrophils mediate vasculitic lesions? Nephrol. Dial. Transplant. 12(2), 249-251 (1997).
54. Segelmark M, Elzouki A, Weislander J, Eriksson S. The PiZ gene of a1-antitrypsin as a determinant of outcome in PR3-ANCA-positive vasculitis. Kidney Int. 48, 844-850 (1995).
55. Harper L, Cockwell P, Adu D, Savage C. Neutrophil priming and apoptosis in ANCA-associated vasculitis. Kidney Int. 59, 1729-1738 (2001).
56. Moosig F, Csernok E, Kumanovics G, Gross WL. Opsonization of apoptotic neutrophils by antineutrophil cytoplasmic antibodies (ANCA) leads to enhanced uptake by macrophages and increased release of tumour necrosis factor-α (TNF-α). Clin. Exp. Immunol. 122(3), 499-503 (2000).
57. Gilligan H, Bredy B, Brady H et al. Antineutrophil cytoplasmic autoantibodies interact with primary granule constituents on the surface of apoptotic neutrophils in the absence of neutrophil priming. J. Exp. Med. 184, 2231-2241 (1996).
58. Kettritz R, Scheumann J, Xu Y, Luft FC, Haller H. TNF-α-accelerated apoptosis abrogates ANCA-mediated neutrophil respiratory burst by a caspase-dependent mechanism. Kidney Int. 61(2), 502-515 (2002).
59. Yang JJ, Tuttle RH, Hogan SL et al. Target antigens for antineutrophil cytoplasmic autoantibodies (ANCA) are on the surface of primed and apoptotic but not unstimulated neutrophils. Clin. Exp. Immunol. 121(1), 165-172 (2000).
60. Durant S, Pederzoli M, Lepelletier Y et al. Apoptosis-induced proteinase 3 membrane expression is independent from degranulation. J. Leukoc. Biol. 75(1), 87-98 (2004).
61. Rosen A, Casciola-Rosen L, Ahearn J. Novel packages of viral and self-antigens are generated during apoptosis. J. Exp. Med. 181, 1557-1561 (1995).
62. Poe M, Blake JT, Boulton DA et al. Human cytotoxic lymphocyte granzyme B. Its purification from granules and the characterization of substrate and inhibitor specificity. J. Biol. Chem. 266(1), 98-103 (1991).
63. Casciola-Rosen L, Andrade F, Ulanet D, Wong WB, Rosen A. Cleavage by granzyme B is strongly predictive of autoantigen status, implications for initiation of autoimmunity. J. Exp. Med. 190(6), 815-826 (1999).
64. Casciola-Rosen LA, Pluta AF, Plotz PH et al. The DNA mismatch repair enzyme PMS1 is a myositis-specific autoantigen. Arthritis Rheum. 44(2), 389-396 (2001).
65. Nagaraju K, Cox A, Casciola-Rosen L, Rosen A. Novel fragments of the Sjogren's syndrome autoantigens α-fodrin and Type 3 muscarinic acetylcholine receptor generated during cytotoxic lymphocyte granule-induced cell death. Arthritis Rheum. 44(10), 2376-2386 (2001).
66. Pinching AJ, Rees AJ, Pussell BA, Lockwood CM, Mitchison RS, Peters DK. Relapses in Wegener's granulomatosis, the role of infection. Br. Med. J. 281, 836-838 (1980).
67. + T cells triggers indoleamine 2,3-dioxygenase activity in dendritic cells. J. Immunol. 172(7), 4100-4110 (2004).
68. Clayton AR, Prue RL, Harper L, Drayson MT, Savage CO. Dendritic cell uptake of human apoptotic and necrotic neutrophils inhibits CD40, CD80, and CD86 expression and reduces allogeneic T cell responses, relevance to systemic vasculitis. Arthritis Rheum. 48(8), 2362-2374 (2003).
69. Rovere P, Sabbadini M, Vallinoto C et al. Dendritic cell presentation of antigens from apoptotic cells in a pro-inflammatory context, role of opsonising antiβ2-glycoprotein I antibodies. Arthritis Rheum. 42, 1412-1420 (1999).
70. Bondanza A, Zimmermann VS, Dell'Antonio G et al. Requirement of dying cells and environmental adjuvants for the induction of autoimmunity. Arthritis Rheum. 50(5), 1549-1560 (2004).
71. Shi Y, Rock KL. Cell death releases endogenous adjuvants that selectively enhance immune surveillance of particulate antigens. Eur. J. Immunol. 32(1), 155-162 (2002).
72. Bendelac A, Medzhitov R. Adjuvants of immunity, harnessing innate immunity to promote adaptive immunity. J. Exp. Med. 195(5), F19-F23 (2002).
73. Li M, Carpio DF, Zheng Y et al. An essential role of the NF-κB/ Toll-like receptor pathway in induction of inflammatory and tissue-repair gene expression by necrotic cells. J. Immunol. 166(12), 7128-7135 (2001).
74. Rifkin IR, Leadbetter EA, Busconi L, Viglianti G, Marshak-Rothstein A. Toll-like receptors, endogenous ligands, and systemic autoimmune disease. Immunol. Rev. 204, 27-442 (2005).
75. Patry YC, Trewick DC, Gregoire M et al. Rats injected with syngenic rat apoptotic neutrophils develop antineutrophil cytoplasmic antibodies. J. Am. Soc. Nephrol. 12(8), 1764-1768 (2001).
76. Chavele M, Shukla D, Keteepe-Arachi T, Fuchs D, Pusey DC. Immune regulation of MPO-ANCA disease is associated with activation of the IDO pathway and tryptophan degredation. J. Am. Soc. Nephrol. (2006) (In Press).
77. Gaskin G, Jayne D. Adjunctive plasma exchange is superior to methylprednisolone in acute renal failure due to ANCA-associated glomerulonephritis. J. Am. Soc. Nephrol. 13, 2A (2002).
78. Keogh KA, Ytterberg SR, Fervenza FC, Carlson KA, Schroeder DR, Specks U. Rituximab for refractory Wegener's granulomatosis, report of a prospective, open-label pilot trial. Am. J. Respir. Crit. Care Med. 173(2), 180-187 (2005).
79. Etanercept plus standard therapy for Wegener's granulomatosis. N. Engl. J. Med. 352(4), 351-361 (2005).
80. Little MA, Bhangal G, Smyth CL et al. Therapeutic effect of antiTNF-α antibodies in an experimental model of antineutrophil cytoplasm antibody-associated systemic vasculitis. J. Am. Soc. Nephrol. 17(1), 160-169 (2006).
81. Booth A, Harper L, Hammad T et al. Prospective study of TNF α blockade with infliximab in antineutrophil cytoplasmic antibody-associated systemic vasculitis. J. Am. Soc. Nephrol. 15(3), 717-721 (2004).